Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety and Efficacy of Sintilimab Combined With Hypofractionated Radiotherapy in MSI-H/dMMR Rectal Cancer: a Prospective, Single-arm, Multicenter, Phase Ib Study

NCT04636008 is registered in ClinicalTrials.gov with West China Hospital as lead sponsor.

NCT NCT04636008
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04636008 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety and Efficacy of Sintilimab Combined With Hypofractionated Radiotherapy in MSI-H/dMMR Rectal Cancer: a Prospective, Single-arm, Multicenter, Phase Ib Study
Lead sponsor
West China Hospital
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 14, 2020
Completion date
December 31, 2024
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anti-pd-1 antibody, mmr deficiency, msi-h, radiotherapy, rectal cancer